These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18836371)

  • 1. The biodistribution of radioiodine on posttherapy iodine-131 scans in thyroid cancer patients with chronic renal failure.
    Aktaş A; Kavak K; Kocabaş B; Aras M; Tütüncü NB; Gençoğlu A
    Nucl Med Commun; 2008 Nov; 29(11):943-8. PubMed ID: 18836371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.
    Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP
    J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
    Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M
    J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer.
    Van Nostrand D; Aiken M; Atkins F; Moreau S; Garcia C; Acio E; Burman K; Wartofsky L
    Thyroid; 2009 Aug; 19(8):849-55. PubMed ID: 19281428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
    J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
    Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
    J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
    Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy.
    Raza H; Khan AU; Hameed A; Khan A
    Nucl Med Commun; 2006 Jun; 27(6):495-9. PubMed ID: 16710103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac blood pool activity on postablation radioiodine imaging.
    Aktaş A; Kocabaş B; Erhamamci S; Gençoğlu A; Liman C
    Ann Nucl Med; 2015 Feb; 29(2):170-6. PubMed ID: 25381484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
    Jentzen W; Balschuweit D; Schmitz J; Freudenberg L; Eising E; Hilbel T; Bockisch A; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2298-306. PubMed ID: 20625723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary gland protection with sialagogues: a case study.
    Van Nostrand D; Atkins F; Bandaru VV; Chennupati SP; Moreau S; Burman K; Wartofsky L
    Thyroid; 2009 Sep; 19(9):1005-8. PubMed ID: 19500022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure.
    Yeyin N; Cavdar I; Uslu L; Abuqbeitah M; Demir M
    Nucl Med Commun; 2016 Mar; 37(3):283-7. PubMed ID: 26619394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.
    Huić D; Medvedec M; Dodig D; Popović S; Ivancević D; Pavlinovic Z; Zuvic M
    Nucl Med Commun; 1996 Oct; 17(10):839-42. PubMed ID: 8951903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease.
    Ortega AJ; Vázquez RG; Cuenca JI; Brocca MA; Castilla J; Martínez JM; González EN
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):29-33. PubMed ID: 26144699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
    Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
    Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic implications of diffuse hepatic uptake following I-131 therapy for differentiated thyroid cancer.
    Ferris HA; Williams G; Parker JA; Garber JR
    Endocr Pract; 2013; 19(2):263-7. PubMed ID: 23529347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.